Managerial turnover is hitting Sarepta Therapeutics Inc as the biotech company prepares to seek regulatory approval for its highprofile drug for a rare and fatal form of muscular dystrophy according to people familiar with the matter On Thursday Sarepta disclosed in a regulatory filing that it had fired its chief scientific officer Arthur Krieg People familiar with the matter said he was fired after raising concerns with members of Sareptas board about Chief Executive Chris Garabedians management of the company As
  